Reconciling Sentinel Node Omission with CDK4/6 Inhibitor Eligibility in HR+/HER2- Early Breast Cancer: A Real-World Cohort Analysis
Omitting sentinel node biopsy in selected patients leads to under-detection of nodal metastasis in a relevant proportion of patients, particularly with cT1c tumors, multi-focal tumors and ILC. As these patients may benefit from more intensive adjuvant treatment, omission of sentinel-node biopsy should be part of decision-making. Future trials should investigate the impact of adjuvant treatment for patients with occult lymph node metastases.
Authors
- B Böer
- Markus Wallwiener (ORCID: https://orcid.org/0000-0002-4139-9340)
- Andreas D. Hartkopf (ORCID: https://orcid.org/0000-0003-1227-1118)
- Léa L. Volmer
- Sara Yvonne Brucker (ORCID: https://orcid.org/0000-0001-8588-1094)
- Alexander Englisch
- Tobias Engler (ORCID: https://orcid.org/0000-0002-8063-2053)
- Markus Hahn (ORCID: https://orcid.org/0000-0002-0284-6566)
- Jannik Daniel Kandzi
Institutions
- University Hospital in Halle (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Clinical Breast Cancer
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1016/j.clbc.2025.10.003
- Citations
- 1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.94